HERON THERAPEUTICS, INC. /DE/ Purchase Obligation, to be Paid, Year Two and Three
HERON THERAPEUTICS, INC. /DE/ (HRTX) had Purchase Obligation, to be Paid, Year Two and Three of $21.20 million as of 2023-12-31, per its 10-K filed 2024-03-12.
Discontinued › Notes › Commitment and Contingencies
us-gaap:PurchaseObligationDueInSecondAndThirdYear · last filed 2024-03-12
- 2023-12-31: Purchase Obligation, to be Paid, Year Two and Three $21.20M.
- 2022-12-31: Purchase Obligation, to be Paid, Year Two and Three $65.00M.
| Period end | Purchase Obligation, to be Paid, Year Two and Three |
|---|---|
| 2023-12-31 | $21.20M 10-K · filed 2024-03-12 |
| 2022-12-31 | $65.00M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |